KCRA3 recently visited the IPN to learn more about our work developing next-generation depression treatments. IPN Director David Olson walked the crew through JRT, an LSD-inspired molecule created by flipping two atoms in LSD's structure, which promotes neuroplasticity in animal studies while showing reduced hallucinogenic potential. As Olson explained, "these drugs are not psychedelics - they were inspired by the neurobiology of psychedelics, but they are completely new compounds." The visit comes as IPN's research continues to move toward the clinic: companies built on this work are now advancing similar drug candidates into human trials for major depressive disorder. Take a look at the segment below.